Physician

Anant Sharma, M.D.

According to 2025 Medicare claims, Anant Sharma, M.D. (NPI: 1154522209) practices hematology/oncology in the Dallas-Plano-Irving, TX market, with the plurality of this provider's patient population coming from Denton, TX. This provider's primary affiliated billing organization is TEXAS ONCOLOGY PA (NPI: 1811944101; TIN: 752131429) and primary practice location at 76201-4315.

Sharma's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 908 traditional Medicare patients, billed 192,603 HCPCS/CPT codes, and received $2,294,211 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,525 prescription claims across 437 beneficiaries totaling $4,994,293 in drug costs, led by Revlimid (Lenalidomide). 2019 DME data shows 12 claims. Open Payments data shows 36 records totaling $1,491. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $900,417 to $2,294,211. Similarly, Part D prescription costs have moved sharply higher in recent years, from $505,372 to $4,994,293. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,295 and ending at $8,280.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	252	102,092	$900,417
2016	450	124,662	$1,679,822
2017	543	118,975	$1,412,197
2018	578	127,987	$1,533,510
2019	666	163,529	$2,032,018
2020	830	198,301	$2,799,998
2021	858	168,987	$2,333,867
2022	893	180,909	$2,668,726
2023	868	156,461	$2,031,542
2024	908	192,603	$2,294,211

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	117	817	$505,372
2016	124	919	$822,359
2017	125	932	$878,321
2018	181	1,200	$960,357
2019	217	1,471	$1,864,531
2020	295	1,801	$2,246,565
2021	347	1,780	$2,558,975
2022	390	2,371	$3,398,281
2023	386	2,472	$2,828,542
2024	437	2,525	$4,994,293

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	18	$315
2016	N/R	144	$9,035
2017	N/R	11	$600
2018	N/R	N/R	N/R
2019	N/R	12	$226
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	329	693	$90
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	485	882	$12
80053	Blood test, comprehensive group of blood chemicals	578	1,530	$10
36415	Insertion of needle into vein for collection of blood sample	580	1,521	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	577	1,638	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	70	1,960	$1,117,361
Brukinsa	Zanubrutinib	45	1,350	$647,338
Xtandi	Enzalutamide	36	1,080	$499,942
Verzenio	Abemaciclib	27	742	$376,670
Pomalyst	Pomalidomide	14	392	$330,777

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	36	$1,491	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Anant Sharma, M.D.?

Tedicare shows public-source Medicare data for Anant Sharma, M.D. (NPI 1154522209), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Anant Sharma, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Anant Sharma, M.D.?

Anant Sharma, M.D. is linked to TEXAS ONCOLOGY PA (billing NPI 1811944101) in the available physician profile data.

Does Anant Sharma, M.D. have Open Payments data?

Anant Sharma, M.D. has 36 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.